Cisplatin exposure alters long-term metabolic phenotype of male, but not female, high-fat diet-fed mice.

This study reveals that cisplatin exposure induces persistent, sex-specific metabolic alterations in high-fat diet-fed mice, characterized by exacerbated dysregulation, leanness, and increased insulin sensitivity in males, while having limited long-term impact on females.

The Gist

Imagine your body as a high-performance car. The pancreas is the fuel pump (specifically, the part that injects insulin to manage sugar), and diet is the type of fuel you put in it. A High-Fat Diet (HFD) is like pouring thick, heavy crude oil into a sports car. Normally, the car's engine (the body) tries to adapt by building a bigger, stronger fuel pump to handle the thick oil. This is called "compensatory hyperinsulinemia"—the body works harder to keep everything running smoothly.

Now, imagine Cisplatin. Cisplatin is a powerful chemotherapy drug used to fight cancer. Think of it as a very effective but slightly toxic "rust remover" that cleans the engine but also leaves some parts a bit shaky.

This study asks: What happens when you put a rusty, shaky fuel pump into a car that's already running on thick, heavy oil? And does the answer change if the car is a "male" model or a "female" model?

Here is the story of what the researchers found, broken down simply:

1. The Setup: The Experiment

The scientists took two groups of mice (male and female).

• Group A ate normal, healthy food (Chow).
• Group B ate a "junk food" diet (High-Fat Diet).
• Then, they gave half of the mice in each group a course of Cisplatin (the chemotherapy) and the other half a harmless saltwater shot (the control).
• They watched them for a long time (18 weeks) to see how their bodies reacted.

2. The Male Mice: A Perfect Storm

The male mice on the junk food diet who got the chemotherapy ended up in a very strange, paradoxical situation.

• The "Ghost" Metabolism: Usually, when male mice eat junk food, they get fat, their blood sugar goes up, and their pancreas pumps out extra insulin to compensate. But the Cisplatin-treated males didn't do this. They stayed thin (they didn't gain weight like the others), yet they still had high blood sugar.
• The Broken Pump: Their pancreas was like a fuel pump that had been damaged by the rust remover. It simply refused to pump out extra insulin, even though the body was screaming for it.
• The Paradox: Here is the weird part: Even though they had high blood sugar (which usually means the body is resistant to insulin), these mice were actually super sensitive to insulin. If you gave them a little insulin, their blood sugar dropped like a stone.
• The Analogy: Imagine a car that is running on thick oil. Normally, the engine revs high to cope. But in these mice, the engine was "stuttering." It wasn't revving high (no extra insulin), so the car couldn't handle the oil (high blood sugar), yet the wheels were still turning very easily (high sensitivity). It's a confusing mix of symptoms that doesn't look like standard diabetes.

The Result: The male mice were stuck in a state of "Type 5 Diabetes" (a rare, non-standard type). They were thin, had high blood sugar, and low insulin. The chemotherapy had broken their body's ability to adapt to the bad diet.

3. The Female Mice: The Resilient Survivors

The female mice told a completely different story.

• The Bounce Back: When the female mice got the chemotherapy, they lost a little weight and had some temporary sugar spikes, just like the males. But then, they recovered.
• The Shield: By the end of the study, the female mice on the junk food diet looked almost exactly like the female mice that didn't get the chemotherapy. Their bodies managed to repair the damage.
• The Analogy: If the male mice were a house that got hit by a storm and the roof never got fixed, the female mice were a house that got hit by the same storm, lost a few shingles, but quickly called a contractor and had the roof fixed before anyone noticed.

4. Why Did This Happen? (The "Why" Behind the Scenes)

The researchers looked inside the cells (the pancreas) to see what was going on.

• In the Males: The chemotherapy had rewritten the "instruction manual" (genes) inside the pancreas cells. It turned down the volume on the genes responsible for making insulin and managing the cell's identity. Even though the cells looked normal under a microscope, they were functionally broken at a molecular level. The "rust remover" had permanently damaged the blueprint.
• In the Females: The chemotherapy didn't change the instruction manual much. The diet caused some changes, but the chemotherapy didn't make it worse. The female cells were able to ignore the damage or repair the blueprint quickly.

The Big Takeaway for Humans

This study is a wake-up call for cancer survivors and doctors.

1. Sex Matters: Men and women react very differently to chemotherapy. What looks like a temporary side effect in women might become a permanent metabolic disaster in men, especially if they have poor eating habits.
2. The "Hidden" Danger: Cancer survivors treated with Cisplatin might not get "classic" Type 2 diabetes (where you are fat and insulin resistant). Instead, they might get this weird "Type 5" style: they stay thin but have high blood sugar because their pancreas just stops working. Doctors might miss this because they are looking for the wrong signs.
3. Diet is Key: If you are a man undergoing chemotherapy, your diet is critical. Putting a damaged engine on a heavy diet is a recipe for long-term trouble.

In a nutshell: Chemotherapy (Cisplatin) acts like a wrench thrown into the engine. In male mice eating junk food, the engine never recovers, leading to a unique and dangerous metabolic state. In female mice, the engine is tough enough to fix itself, even with the wrench in it. This suggests that cancer survivors, particularly men, need very specific, long-term monitoring of their blood sugar and metabolism.

Technical Summary

1. Problem Statement

Cancer survivors treated with cisplatin (a platinum-based chemotherapeutic agent) face an elevated risk of developing metabolic complications, including Type 2 Diabetes (T2D) and metabolic syndrome. While previous studies established that cisplatin acutely disrupts insulin secretion in vitro and reduces plasma insulin levels in vivo within two weeks, the long-term metabolic consequences of cisplatin exposure, particularly in the context of pre-existing metabolic stress (such as obesity induced by a High-Fat Diet, HFD), remain uncharacterized. Furthermore, it is unclear if these effects exhibit sex-specific differences. The study aims to determine how cisplatin interacts with HFD-induced metabolic stress to alter long-term glucose homeostasis, insulin secretion, and islet function in male and female mice.

2. Methodology

• Animal Model: Male and female C57Bl/6 mice (mixed J/N background) were utilized.
• Experimental Design:
  • Diet: Mice were fed either standard rodent chow or a 45 kcal% High-Fat Diet (HFD) starting at ~14 weeks of age.
  • Treatment: At ~18 weeks (after 4 weeks on diet), mice received intraperitoneal injections of either saline (vehicle) or 2 mg/kg cisplatin every other day for 14 days (7 injections total; cumulative dose 14 mg/kg).
  • Groups: Four groups per sex: Vehicle-Chow, Cisplatin-Chow, Vehicle-HFD, Cisplatin-HFD ($n=10-12$/group/sex).
  • Duration: Mice were monitored for 18 weeks post-exposure (total study duration ~38 weeks of age).
• Assessments:
  • In Vivo: Monthly body weight (BW), fasting blood glucose (BG), Glucose Tolerance Tests (ipGTT), and Insulin Tolerance Tests (ipITT). Plasma insulin was measured via ELISA.
  • Ex Vivo (at 18 weeks): Islet isolation for Glucose-Stimulated Insulin Secretion (GSIS) assays, oxygen consumption rate (Seahorse XF analyzer), and insulin content quantification.
  • Histology & Morphology: Transmission Electron Microscopy (TEM) for $\beta$-cell granule integrity; Immunofluorescence for $\beta$-cell mass (% insulin+ area), proinsulin accumulation, and MAFA expression.
  • Transcriptomics: Quantitative real-time PCR (qPCR) on isolated islets and liver tissue to assess gene expression related to insulin processing, $\beta$-cell identity, and gluconeogenesis.

3. Key Contributions

• Sex-Specific Long-Term Effects: The study provides the first evidence that the long-term metabolic impact of cisplatin is highly sex-dependent. While cisplatin causes persistent, severe metabolic dysregulation in HFD-fed males, female mice largely recover or show only transient effects.
• Novel Phenotype Identification: The authors characterize a unique "Type 5 diabetes"-like phenotype in cisplatin-treated HFD males, distinct from classic T2D, characterized by low body weight, severe hypoinsulinemia, glucose intolerance, and paradoxically increased insulin sensitivity.
• Mechanistic Insight: The study decouples the effects of cisplatin from diet-induced obesity, showing that cisplatin disrupts the canonical adaptive response of $\beta$-cells to HFD (i.e., compensatory hyperinsulinemia and islet hypertrophy).

4. Key Results

A. Metabolic Phenotype in Male Mice

• Body Weight: Cisplatin-HFD males failed to gain weight despite HFD feeding, remaining ~30% lighter than Vehicle-HFD males by week 18. Cisplatin-Chow males regained weight to match controls.
• Glucose Homeostasis:
  • Cisplatin-HFD males remained glucose intolerant throughout the 18-week period.
  • Unlike Vehicle-HFD males (who developed compensatory hyperinsulinemia), Cisplatin-HFD males exhibited persistent hypoinsulinemia (approx. 2-fold reduction in plasma insulin) and failed to mount a compensatory insulin response.
• Insulin Sensitivity: Paradoxically, Cisplatin-HFD males displayed increased insulin sensitivity (lower blood glucose drop post-insulin) compared to all other groups, suggesting a dissociation between glucose intolerance and peripheral insulin resistance.
• Islet Morphology & Function:
  • No loss of $\beta$-cell mass or insulin granule depletion was observed via TEM or immunofluorescence.
  • However, Cisplatin-HFD males failed to exhibit islet hypertrophy (enlargement) typically seen in HFD-fed controls, indicating a blunted adaptive response.
  • Ex vivo GSIS and oxygen consumption showed no major differences, suggesting the defect lies in the in vivo regulation or secretion dynamics rather than intrinsic islet capacity.
• Transcriptional Changes: Cisplatin broadly downregulated key $\beta$-cell identity and function genes in males regardless of diet, including Pdx1, Nkx6-1, Pcsk1/2 (prohormone convertases), and Gck. Ins1 was downregulated in Cisplatin-Chow, while Gcg (glucagon) was upregulated in Cisplatin-HFD.

B. Metabolic Phenotype in Female Mice

• Recovery: Female mice showed minimal long-term effects. Cisplatin-HFD females experienced transient weight loss and mild hyperglycemia but recovered to match Vehicle-HFD controls by week 9.
• Glucose/Insulin: No significant long-term differences in glucose tolerance, plasma insulin, or insulin sensitivity were observed between Cisplatin and Vehicle groups.
• Transcriptional Changes: Gene expression changes in females were primarily driven by diet (HFD) rather than cisplatin. Cisplatin had little effect on $\beta$-cell identity markers (Mafa, Pdx1, Nkx6-1).
• Proinsulin: Cisplatin-HFD females showed a transient increase in cytoplasmic proinsulin accumulation, suggesting a mild defect in insulin processing that did not translate to long-term metabolic failure.

5. Significance and Implications

• Clinical Relevance: The findings suggest that cancer survivors (particularly males) receiving cisplatin who have pre-existing metabolic stress (obesity/HFD) are at high risk for a specific, under-recognized form of diabetes. This "Type 5" phenotype (low BMI, low insulin, high glucose, high sensitivity) differs from classic T2D and may be misdiagnosed or overlooked if clinicians expect only insulin resistance.
• Sex as a Biological Variable: The study underscores the critical need to incorporate sex as a biological variable in oncology and metabolic research, as females appear protected from the long-term synergistic toxicity of cisplatin and HFD.
• Mechanism of Injury: The data suggests cisplatin causes persistent $\beta$-cell injury that prevents the necessary plasticity (hypertrophy and hyperinsulinemia) required to adapt to metabolic stress. The lack of compensatory mechanisms leads to a state of insulin deficiency despite high metabolic demand.
• Future Directions: The authors recommend monitoring metabolic health in cancer survivors beyond the acute treatment phase and investigating the role of $\beta$-cell KATP channels and nutrient handling in the observed phenotype.

In summary, this paper demonstrates that cisplatin exposure fundamentally alters the long-term metabolic trajectory of male mice under metabolic stress, creating a persistent state of insulin deficiency and glucose intolerance that is distinct from classic Type 2 diabetes, while female mice remain largely resilient to these long-term effects.